Please login to the form below

Not currently logged in
Email:
Password:

migraines

This page shows the latest migraines news and features for those working in and with pharma, biotech and healthcare.

Pricing pressures peg back Lilly’s growth products

Pricing pressures peg back Lilly’s growth products

Lilly has other new medicines rolling out to help it manage the Cialis patent cliff, and third-to-market CGRP inhibitor for migraine – Emgality (galcanezumab) - added $14m in the quarter, overtaking

Latest news

  • Alcon spun off, leaner Novartis raises profit forecast Alcon spun off, leaner Novartis raises profit forecast

    The firm has also hit an unexpected problem in the last few weeks in connection with an other major new brand, migraine treatment Aimovig, with marketing partner Amgen looking to break

  • Novartis and Amgen come to blows over migraine partnership Novartis and Amgen come to blows over migraine partnership

    Aimovig was approved by the FDA last year as a once-monthly, self-injected preventive treatment for migraines, and was the first CGRP inhibitor to reach the market. ... Analysts think the category will support multibillion dollar sales, driven by the

  • Teva’s migraine injection approved in Europe Teva’s migraine injection approved in Europe

    for migraine prevention, gaining European approval in August last year, followed by Lilly's Emgality in November. ... The FDA also recently accepted an NDA from Botox developer Allergan, which filed its oral CGRP ubrogepant for the acute treatment of

  • Teva will have to endure revenue 'trough' in 2019 Teva will have to endure revenue 'trough' in 2019

    To reverse the trend, Teva needs new products such as migraine prevention therapy Ajovy (fremanezumab) and Austedo (deutetrabenazine) for tardive dyskinesia and chorea associated with Huntington’s disease to ramp up

  • Trulicity’s ascent lifts Lilly Trulicity’s ascent lifts Lilly

    Meanwhile, in Europe, the company gained EU-wide approval in November for Emgality, its contender in the new CGRP inhibitor class of migraine prevention medicines.

More from news
Approximately 22 fully matching, plus 132 partially matching documents found.

Latest Intelligence

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    Published adherence in migraine-prophylaxis (as a comparable indication) indicates 92.6% adherent at one month, 40.7% at two months, 30.9% at three months, 24.8% at four months,

  • Deal Watch January 2018

    Teva’s CGRP patent portfolio to develop, manufacture and commercialise eptinezumab, its phase III CGRP antibody for the treatment of migraine.  In exchange for the licence, Alder will withdraw its appeal

  • The good, the bad and the ugly The good, the bad and the ugly

    Three CGRP monoclonal antibodies will launch in the US for migraine in 2018 - with a fourth anticipated in 2019.

  • The cultural construction of illness The cultural construction of illness

    Some years ago, we were asked to advise on marketing a cure for migraines in the UK. ... In this world, migraines were associated with ideas of the overly sensitive, or even hysterical woman, requiring rational male intervention to bring her back to her

  • Ditch the data? Ditch the data?

    Around one in seven people suffer from migraines, and these can impact severely on quality-of-life. ... When a migraine hits, she needs to shut herself in a dark room in silence.

More from intelligence
Approximately 1 fully matching, plus 23 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Playing Mind Games
To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists
P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....

Infographics